2
项与 ChAdV63.HIVconsv(University of Oxford) 相关的临床试验Research In Viral Eradication of HIV Reservoirs
This study will be a two-arm prospective 1:1 randomised controlled trial comparing:
Arm A: cART preferably including raltegravir (combination ART cART - control) Arm B: cART preferably including raltegravir (cART) plus ChAdV63.HIVconsv (ChAd) prime and MVA.HIVconsv (MVA) boost vaccines; followed by a 28-day course of vorinostat (10 doses in total).
We hypothesise that this intervention in primary HIV infection will confer a significant reduction in the latent HIV reservoir when compared with cART alone.
.
A Randomized Single-blind Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Three Candidate HIV-1 Vaccines, pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv, Administered in Combination to Healthy HIV 1 Uninfected Adults
This is a randomised, placebo-controlled, single-blind study designed to evaluate the safety and immunogenicity of three novel HIV vaccines.
100 项与 ChAdV63.HIVconsv(University of Oxford) 相关的临床结果
100 项与 ChAdV63.HIVconsv(University of Oxford) 相关的转化医学
100 项与 ChAdV63.HIVconsv(University of Oxford) 相关的专利(医药)
100 项与 ChAdV63.HIVconsv(University of Oxford) 相关的药物交易